"Commercialization Readiness from Preclinical to 1st Launch: The First Time CEO’s Playbook" on February 27 will equip early-stage biotechnology leaders with the commercialization knowledge they need to strategically position their organizations for financing success and meeting critical commercial milestones.
The drug development process is complex and multifaceted, and understanding the commercialization considerations at each phase is vital. From preclinical to first product launch, this one-day course will help biotech executives make informed strategic choices for long-term success.
This interactive course will cover phase-specific market analysis, including a competitive landscape assessment, regulatory considerations, the Commercialization Roadmap development, FTEs and dollar spend, market access pricing and reimbursement, value proposition development, and go-to-market preparation.
Russ Belden, founder and CEO of Bridge, will guide you through this course by sharing real-world examples and valuable insights. Russ is a biotech commercialization leader with over 36 years of senior operational experience in the preclinical to first launch space.
Developed by Biotech Primer, BIO’s official education partner, “Commercialization Readiness: From Phase 1 to 1st Launch” will empower you to navigate the commercialization journey effectively. Please note that this course runs concurrently with sessions in the BIO CEO & Investor Conference program.